Literature DB >> 33915594

[Functional Hypersalivation in children and adults - therapy under consideration of recent guideline].

Armin Steffen, Saskia Rohrbach-Volland.   

Abstract

A functional hypersalivation reduces patient's quality of life by the need of repeated changes of cloths, skin damage around the mouth and reduced personal contacts. The indication to treat hypersalivation is justified furthermore when respiratory infections by saliva aspiration occur. Transnasal swallowing endoscopy allows to evaluate sufficiently dysphagia with limited risks. With this method therapy options can be judged for effectiveness. There are other additional radiologic assessments to complete diagnostic. Swallowing therapy should be initiated as first-line approach for hypersalivation and offers several treatment concepts to overcome the syndrome. Glycopyrrolate bromid received approval for children and adolescents as it reduces saliva flow relevantly with limited risk. Other anticholinergic drugs are restricted in use because of their side effects and off-label-use situation. Ultrasound guided injections of botulinum toxine in salivary glands are an established treatment option since decades. Meanwhile, the evidence for this method has improved, so Incobotulinum toxine is an approved therapy for chronic hypersalivation in adults, whereby new injections are needed about every four months. In the light of effective medical options, surgical approaches such as salivary duct relocation are recommended less often today because of invasiveness and failure. Radiotherapy is reserved mainly for neurodegenerative diseases and shows good response, but the cancer induction risks need to be discussed. A close follow-up regime is necessary to establish compliance not only by the patient, but also by his family and caregivers. By this, treatment effects can be optimized and therapies can be adjusted individually. Thieme. All rights reserved.

Entities:  

Year:  2021        PMID: 33915594     DOI: 10.1055/a-1355-7642

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  2 in total

1.  Current Aspects of Treatment Options of Chronic Sialorrhea in Children.

Authors:  Stefan Bittmann; Elisabeth Luchter; Lara Bittmann; Elena Moschuring-Alieva; Gloria Villalon
Journal:  J Clin Med Res       Date:  2022-06-27

2.  [Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults].

Authors:  Wolfgang H Jost; Tobias Bäumer; Andrea Bevot; Ulrich Birkmann; Carsten Buhmann; Maria Grosheva; Orlando Guntinas-Lichius; Ute Mlynczak; Sebastian Paus; Christina Pflug; Sebastian Schröder; Armin Steffen; Bernd Wilken; Steffen Berweck
Journal:  Fortschr Neurol Psychiatr       Date:  2022-04-22       Impact factor: 0.760

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.